02:08 PM EDT, 06/10/2025 (MT Newswires) -- (Updates with Eli Lilly's ( LLY ) response to a request for comment in the third paragraph.)

Eli Lilly ( LLY ) will only partner with telehealth firms that stop selling copycat versions of its weight-loss drug, Bloomberg reported Tuesday, citing Chief Financial Officer Lucas Montarce, speaking at a conference.

The company's recent agreements with Ro and LifeMD ( LFMD ) prohibit them from selling compounded versions of Lilly's Zepbound and Novo Nordisk's ( NVO ) Wegovy, Montarce said, according to the report.

"Our LillyDirect self-pay pharmacy integration agreements require telehealth companies to follow the law," an Eli Lilly ( LLY ) spokesperson told MT Newswires via email. "Anyone continuing to sell mass compounded tirzepatide or semaglutide products, including by referring to them as "personalized," "tailored" or something similar, is breaking the law and putting patient safety at risk. We will continue to work with regulators and take other legal actions to stop them."

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 801.30, Change: +31.33, Percent Change: +4.07